miltefosine has been researched along with Malaria in 6 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum." | 7.81 | New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents. ( Abd El Razik, HA; Bekhit, AA; Bekhit, Ael-D; El-Agroudy, EJ; El-Miligy, MM; Hassan, AM, 2015) |
| "To obtain a high antimalarial activity with neocryptolepine derivatives, modifying and changing the side chains at the C11 position with varying the substituents of an electron-withdrawing or electron-donating nature at the C2 position for a SAR study were executed." | 7.79 | Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines. ( El Sayed, I; Inokuchi, T; Kaiser, M; Lu, WJ; Maeda, T; Mei, ZW; Pang, CQ; Peng, W; Wang, L, 2013) |
| " The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum." | 3.81 | New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents. ( Abd El Razik, HA; Bekhit, AA; Bekhit, Ael-D; El-Agroudy, EJ; El-Miligy, MM; Hassan, AM, 2015) |
| "To obtain a high antimalarial activity with neocryptolepine derivatives, modifying and changing the side chains at the C11 position with varying the substituents of an electron-withdrawing or electron-donating nature at the C2 position for a SAR study were executed." | 3.79 | Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines. ( El Sayed, I; Inokuchi, T; Kaiser, M; Lu, WJ; Maeda, T; Mei, ZW; Pang, CQ; Peng, W; Wang, L, 2013) |
| " In this study, a new semi-synthetic berberine analogue, 5,6-didehydro-8,8-diethyl-13-oxodihydroberberine chloride (1), showed nanomolar level potency against in vitro models of leishmaniasis, malaria, and trypanosomiasis as well as activity in an in vivo visceral leishmaniasis model." | 3.77 | Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. ( Anklin, C; Bahar, M; Deng, Y; Doskotch, RW; Drew, ME; Gil, RR; He, S; Kinghorn, AD; Navarro-Vázquez, A; Pandharkar, T; Werbovetz, KA; Zhu, X, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahar, M | 1 |
| Deng, Y | 1 |
| Zhu, X | 1 |
| He, S | 1 |
| Pandharkar, T | 1 |
| Drew, ME | 1 |
| Navarro-Vázquez, A | 1 |
| Anklin, C | 1 |
| Gil, RR | 1 |
| Doskotch, RW | 1 |
| Werbovetz, KA | 1 |
| Kinghorn, AD | 1 |
| Shi, XL | 1 |
| Ge, JF | 1 |
| Liu, BQ | 1 |
| Kaiser, M | 3 |
| Wittlin, S | 1 |
| Brun, R | 1 |
| Ihara, M | 1 |
| Liew, LP | 1 |
| Copp, BR | 1 |
| Mei, ZW | 1 |
| Wang, L | 1 |
| Lu, WJ | 1 |
| Pang, CQ | 1 |
| Maeda, T | 1 |
| Peng, W | 1 |
| El Sayed, I | 1 |
| Inokuchi, T | 1 |
| Giannini, G | 1 |
| Battistuzzi, G | 1 |
| Vignola, D | 1 |
| Bekhit, AA | 1 |
| Hassan, AM | 1 |
| Abd El Razik, HA | 1 |
| El-Miligy, MM | 1 |
| El-Agroudy, EJ | 1 |
| Bekhit, Ael-D | 1 |
6 other studies available for miltefosine and Malaria
| Article | Year |
|---|---|
Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
Topics: Animals; Antiprotozoal Agents; Berberine; Chlorocebus aethiops; Disease Models, Animal; Inhibitory C | 2011 |
Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Drug Design; Inhibitory Concentration 50; Leishmania d | 2011 |
Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.
Topics: Acetamides; Animals; Antimalarials; Drug Discovery; Inhibitory Concentration 50; Malaria; Molecular | 2013 |
Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines.
Topics: Alkaloids; Animals; Antimalarials; Cell Line; Chloroquine; Drug Resistance; Indoles; Malaria; Mice; | 2013 |
Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Topics: Animals; Antimalarials; Cell Line, Tumor; Dipeptides; Disease Models, Animal; Histone Deacetylase In | 2015 |
New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
Topics: Animals; Antimalarials; Chemistry Techniques, Synthetic; Chloroquine; Drug Design; Drug Evaluation, | 2015 |